Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Two years ago, as Iveric Bio went through late-stage studies of its main experimental drug, it began attracting interest from potential buyers. Five companies ended …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Who else want­ed to buy Iver­ic? Be­fore the $5.9B Astel­las deal, five bio­phar­ma com­pa­nies took a look

Senior Reporter

Senior Biopharma Correspondent

Sign up to read this article for free.

Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look